Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
Acquired Scynexis, Inc.
|
| gptkbp:allies |
Forms strategic alliances with other companies
|
| gptkbp:awards |
Received multiple industry awards
|
| gptkbp:biopharmaceuticals |
Involved in biopharmaceuticals development
|
| gptkbp:ceo |
Isao Teshirogi
|
| gptkbp:clinical_trial |
Focuses on drug development for unmet medical needs
Conducts extensive clinical research Conducts Phase III clinical trials Conducts clinical trials for new drugs Collects clinical data for research purposes Conducts healthcare research initiatives Involved in clinical development of new therapies |
| gptkbp:collaboration |
Works with academic institutions
|
| gptkbp:collaborations |
Engages in research collaboration with universities
Partners with global research organizations |
| gptkbp:community_engagement |
Engages with local communities
|
| gptkbp:community_health |
Contributes to global health initiatives
|
| gptkbp:drug_pipeline |
Has a robust drug pipeline
|
| gptkbp:drug_safety |
Prioritizes drug safety in development
|
| gptkbp:economic_impact |
Pursues market expansion strategies
|
| gptkbp:employees |
Approximately 5,000
|
| gptkbp:financial_support |
Provides patient support programs
|
| gptkbp:founded |
1878
|
| gptkbp:founder |
Taikichiro Shiono
|
| gptkbp:funding |
Allocates funding for research projects
|
| gptkbp:global_presence |
Operates in multiple countries
|
| gptkbp:headquarters |
gptkb:Osaka,_Japan
|
| gptkbp:healthcare |
Focuses on healthcare innovation
Promotes access to healthcare solutions Seeks drug approval from regulatory agencies |
| https://www.w3.org/2000/01/rdf-schema#label |
Shionogi Inc.
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:innovation |
Emphasizes innovation in drug development
|
| gptkbp:invention |
Holds numerous patents in pharmaceuticals
|
| gptkbp:investment |
Invests in biotechnology startups
Maintains investor relations programs |
| gptkbp:market |
Conducts market research for pharmaceuticals
Operates in the global pharmaceutical market |
| gptkbp:market_launch |
Introduced new antibiotic in 2019
Launched new antiviral treatment in 2020 Released pain management drug in 2021 |
| gptkbp:partnership |
Collaboration with Merck & Co.
|
| gptkbp:partnerships |
Establishes partnerships with healthcare providers
Forms healthcare partnerships for better access |
| gptkbp:products |
Antibiotics
Antiviral drugs Pain relief medications |
| gptkbp:regulatory_compliance |
Seeks regulatory approval for new drugs
|
| gptkbp:research_areas |
Focuses on various therapeutic areas
|
| gptkbp:research_focus |
Infectious diseases
Metabolic diseases Central nervous system disorders |
| gptkbp:revenue |
$1.5 billion (2021)
|
| gptkbp:social_responsibility |
Engages in community health initiatives
|
| gptkbp:stock_exchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stock_symbol |
4507
|
| gptkbp:subsidiary |
Shionogi Pharma, Inc.
|
| gptkbp:supply_chain |
Manages a global supply chain for pharmaceuticals
|
| gptkbp:sustainability |
Focuses on sustainable practices
|
| gptkbp:therapeutics |
Develops therapeutics for various conditions
|
| gptkbp:training |
Provides employee training programs
|
| gptkbp:treatment |
Aims to improve clinical outcomes for patients
Studies health outcomes of treatments |
| gptkbp:type_of_care |
Enhances patient care through innovative solutions
|
| gptkbp:website |
www.shionogi.com
|
| gptkbp:bfsParent |
gptkb:Shionogi
|
| gptkbp:bfsLayer |
6
|